Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00179127
Status:
COMPLETED
Last Update Posted:
2018-07-16
First Post:
2005-09-13
Brief Title:
Use of Insulin Glargine to Treat Diabetic Ketoacidosis
Sponsor:
Vanderbilt University Medical Center
Organization:
Vanderbilt University Medical Center
Study Overview
Official Title:
Early Use of Insulin Glargine in Diabetic Ketoacidosis
Status:
COMPLETED
Status Verified Date:
2018-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the effects of the addition of insulin glargine during the early phase of moderate to severe Diabetic Ketoacidosis DKA in children
The investigators hypothesize that the addition of insulin glargine during the early phase of management of DKA will accelerate acidosis correction decrease the length of insulin infusion and decrease the total intensive care unit time in children admitted to the ICU
The investigators hypothesize that the addition of insulin glargine during the early phase of management of DKA will accelerate acidosis correction decrease the length of insulin infusion and decrease the total intensive care unit time in children admitted to the ICU
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None